

THE POWER OF IMAGERY IN CLINICAL MEDICINE: LEVERAGING CLINICAL PHOTOS FROM THE VISIBLE STUDY TO FOSTER CONVERSATIONS BETWEEN CLINICIANS AND PATIENTS



Adrian O Rodriguez, Linda Stein Gold, Mona Shahriari, Andrew Alexis, Olivia Choi, Daphne Chan, Elizabeth Skobelev, Sancharitha Ramji, Amy McMichael, Susan C Taylor, Seemal R Desai,


¹Nashville Skin Comprehensive Dermatology Center, Nashville, TN, USA; ²Henry Ford Medicine, New York, NY, USA; ³Yale University School of Medicine, Central Connecticut Dermatology, New Haven, CT, USA; ⁴Weill Cornell Medicine, New York, NY, USA; ⁵Janssen Scientific Affairs, LLC, PA, USA; ⁶Wake Forest School of Medicine, Winston-Salem, NC, USA; ⁷Department of Dermatology, Perelman Center for Advanced Medicine, Philadelphia, PA, USA; ⁸University of Texas Southwestern and Innovative Dermatology, Plano, TX, USA

BACKGROUND/OBJECTIVE

- Psoriasis (PsO) is often described as well-defined, inflamed, red or pink plaques with scaling; however, in individuals with skin of color (SOC), this description is not always accurate^{1,2}
- Only 4–19% of images in dermatology textbooks are on darker skin tones³
- VISIBLE (NCT05272150) evaluated efficacy of guselkumab (GUS) versus placebo (PBO) in participants (pts) with moderate-to-severe plaque PsO or scalp PsO in SOC
- As a first-of-its-kind study 100% dedicated to people of color with PsO, VISIBLE enabled the development of a digital photo library to address the clinical knowledge gap for visualizing PsO in a range of skin tones; here we present a snapshot of this tool
- To compile a PsO digital photo library from VISIBLE clinical trial pts with a range of skin tones
- To educate providers and patients on the clinical features of PsO in all skin tones
- To improve diagnostic accuracy of PsO across all skin tones

measurement of non-sun exposed skin)


METHODS: THE VISIBLE STUDY



visualization

- Pts in the trial gave consent for the medical use of their photos
- Photography was done using standard and cross polarized lighting; cross polarization enhances visualization of erythema and pigmentation, especially in SOC
- Standard positions were used for body and scalp photos, with software assistance to match positioning between visits
- The protocol included photo collection at screening and Weeks 0, 4, 12, 16, 20, 24, 32, 44, 48, 52, 68, 84, and 100

VISIBLE REPRESENTS A DIVERSE POPULATION ACROSS SKIN TONES




Psoriasis my be more challenging to diagnose on diverse skin tones because it may require a broader differential, which may explain when it is 4x more likely to require a biopsy for diagnosis of skin of color⁴ These are photos that do not fit the classic morphology description of "well-demarcated erythematous plaque with silvery scale" Lichen Planus Tinea Versicolor Atopic Dermatitis Pityriasis Rubra Pilaris Crusted Scabies Drug Eruption Erythema Dyschromicum Perstans Wrist Back Torso


PSORIASIS MORPHOLOGY MAY VARY ACROSS SKIN TONES

• Morphology descriptors include: - color (violaceous, brown, pink, etc), scale (ostracoeus, micaceous, thick, etc), size (large, agminated small plaques, confluent, etc)



PHOTO LIBRARY INTERFACE ELEMENTS Health Care Professionals (HCPs) and patients can find the most searched for PsO manifestations or browse curated libraries of images HCPs can filter the search criteria to explore subsets of PsO images





Apply filters to search for specific images based on:

CONCLUSIONS

- The first-of-its-kind VISIBLE study recruited a diverse population of pts with moderate-to-severe plaque PsO across all skin tones and was intentionally designed to collect standardized serial photos to help address the dearth of photos of darker skin tones in medical and educational materials
- VISIBLE pts' Ps0:
- ranged in color from traditional erythematous spectrum to violaceous and brown
- exhibited diverse morphology ranging from small, scattered plaques, to large, thin, or very thick plaques, with varied scale features even within the same pt
- exhibited a broader differential for psoriasis across diverse skin tones because of the variations in color and morphology
- The VISIBLE study starts a photo library that is an expandable, searchable, digital platform for bridging education gaps around treating those currently underrepresented

PRESENTED AT: Maui Derm Hawaii 2025; Maui, Hawaii, USA; January 20-24, 2025. References: 1. Khanna R, et al. Dermatol. 2018;19(3):405–23. 3. Bellicoso E, et al. J Cutins Need 2022;175:1298-1304) and was funded by Janckie Discourses: AA has received grants (funds to institution) from AbbVie, Amgen, Arcutis, Castle, Dermavant, Eli Lilly, EPI, Galderma, and LEO; has served on an advisory board or consulted for AbbVie, Amgen, Arcutis, Castle, Dermavant, Eli Lilly, EPI, Galderma, and LEO; has served on an advisory board or consulted for AbbVie, Amgen, Arcutis, Castle, Dermavent, Galderma, and LEO; has served on an advisory board or consulted for AbbVie, Amgen, Arcutis, Castle, Dermavant, Eli Lilly, EPI, Galderma, and LEO; has served as a speaker for Bristol Myers Squibb, Janssen, Johnson & Johnson, L'Oréal, Prizer, and others. He also serves as a consultant and/or investigator for a variety of different organizations including Eli Lilly, EPI Health, Janssen, Lilly, EPI Health, Janssen, Leo, Novartis, Bristol Myers Squibb, Discours, Prizer, Regeneron, Sanofi-Genzyme, as a consultant and Johnson, L'Oréal, Prizer, Regeneron, Sanofi-Genzyme, as a consultant and Johnson, L'Oréal, Prizer, Regeneron, Sanofi-Genzyme, and Sanofi-Genzyme, Sanofi-Genzyme, Sanofi-Genzyme, and Sanofi-Genzyme, Inc. Lilly, Sanofi-Genzyme, Sa